Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
optical source : Www.biospace.com save search
Precision Optics Reports Second Quarter Fiscal Year 2024 Financial Results
Published: 2024-02-14 (Crawled : 00:00) - biospace.com/
POCI | $5.5105 2.4K
|
Manufacturing
|
| O: 4.1%
H: 0.16%
C: -0.66%
precision year financial results
Precision Optics Corporation Schedules Second Quarter of Fiscal Year 2024 Conference Call for Wednesday, February 14, 2024
Published: 2024-02-08 (Crawled : 23:00) - biospace.com/
POCI | $5.5105 2.4K
|
Manufacturing
|
| O: 0.16%
H: 0.0%
C: -1.64%
conference precision year corporation
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
Published: 2024-01-23 (Crawled : 15:30) - biospace.com/
INVO | $1.36 78.95% 3.6M
|
Health Technology
|
| O: 3.88%
H: 9.35%
C: 2.8%
acquire program therapy
Precision Optics Reports First Quarter Fiscal Year 2024 Financial Results
Published: 2023-11-14 (Crawled : 00:00) - biospace.com/
POCI | $5.5105 2.4K
|
Manufacturing
|
| O: 4.51%
H: 3.19%
C: -4.15%
year financial results
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2023-06-22 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.25%
H: 0.75%
C: 0.04%
tepezza disease active japan positive treatment thyroid topline eye trial therapeutics
Zomedica Launches Revolutionary TRUVIEW(TM) Digital Microscope with Advanced Optics, Automated Slide Preparation, and Telepathology Services
Published: 2023-06-09 (Crawled : 12:00) - biospace.com/
ZOM | $0.1308 0.38% 1.5M
|
Miscellaneous
|
| O: 0.76%
H: 0.25%
C: -2.01%
services
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
Published: 2023-04-25 (Crawled : 12:00) - biospace.com/
STOK | News | $11.76 0.34% 480K
|
Health Technology
|
| O: 0.62%
H: 4.79%
C: -0.49%
stk-002 authorization therapeutics study
New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2023-03-14 (Crawled : 18:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.32%
H: 0.1%
C: -0.09%
uplizna show
Precision Optics Announces Receipt of $2.3 Million Follow-On Production Order from Large Medical Device Company for Otoscopy Application
Published: 2023-01-17 (Crawled : 15:00) - biospace.com/
POCI | $5.5105 2.4K
|
Manufacturing
| Email alert
Add to watchlist
PEYED | $6.2
|
n/a
| Email alert
Add to watchlist
device medical order application
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2022-11-16 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.04%
H: 1.08%
C: -0.54%
tepezza treatment thyroid disease active japan eye trial therapeutics
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
Published: 2022-11-04 (Crawled : 17:00) - biospace.com/
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: 1.32%
H: 14.6%
C: -3.5%
advm-022 trial positive injection results study
Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)
Published: 2022-08-25 (Crawled : 12:00) - biospace.com/
STOK | News | $11.76 0.34% 480K
|
Health Technology
|
| O: 1.16%
H: 0.0%
C: -3.16%
therapeutics living study
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD
Published: 2022-06-09 (Crawled : 14:00) - biospace.com/
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: -0.92%
H: 2.78%
C: -0.93%
advm-022 injection
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2022-02-23 (Crawled : 19:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.97%
H: 0.38%
C: -2.35%
treatment eye eye disease trial therapeutics disease active phase 3
Ocutrx Technologies Leads the Field With Three Patents On Near-eye Pupil-forming Catadioptric Optical EngineThe company received praise from its investment banking firm, Boustead Securities, LLC
Published: 2021-11-17 (Crawled : 16:00) - biospace.com/
KODK | $4.725 3.62% 220K
|
Electronic Technology
|
| O: -1.01%
H: 1.02%
C: -1.89%
eye optical patent
Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections
Published: 2021-10-01 (Crawled : 00:20) - biospace.com/
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
injection
Vyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population Spheroids
Published: 2021-07-13 (Crawled : 13:00) - biospace.com/
VYNT | $0.194 -8.51% 19K
|
Health Care and Social Assistan...
|
| O: 1.47%
H: 0.29%
C: -0.29%
optical patent
Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)
Published: 2021-05-04 (Crawled : 13:00) - biospace.com/
STOK | News | $11.76 0.34% 480K
|
Health Technology
|
| O: -0.44%
H: 1.74%
C: -2.91%
leo
DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF $750,000 FOR POINT-OF-CARE OPTICAL BLOOD VOLUME ANALYZER
Published: 2021-03-15 (Crawled : 14:00) - biospace.com/
DXR | $9.6135 680
|
Health Technology
|
| O: 2.06%
H: 2.42%
C: 2.42%
blood optical contract
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.